For example, RORγ agonists, which can activate BMAL1 transcription [48], attenuate the expression of PD-1 receptors, and LYC-55716, a RORy inhibitor, is currently under a Phase 1 trial used in combination with pembrolizumab for NSCLC (NCT03396497). This evidence concerns the gene BMAL1 and non-small cell lung carcinoma.